| Compound |
Analytes |
Species |
Matrix |
LLOQ- ULOQ |
Validated Sample Vol. (mL) |
Method |
Anti- coagulant |
| Adefovir |
Adefovir |
Human |
P |
10.0-10,000 ng/mL |
0.100 |
LC-MS/MS |
6 |
|
Ritonavir |
Human |
P |
10.0-10,000 ng/mL |
0.100 |
LC-MS/MS |
6 |
| |
| Amprenavir |
Amprenavir |
Human |
P |
10.0-10,000 ng/mL |
0.100 |
LC-MS/MS |
6 |
|
Indinavir |
Human |
P |
10.0-10,000 ng/mL |
0.100 |
LC-MS/MS |
6 |
|
Nelfinavir |
Human |
P |
10.0-10,000 ng/mL |
0.100 |
LC-MS/MS |
6 |
|
Ritonavir |
Human |
P |
10.0-10,000 ng/mL |
0.100 |
LC-MS/MS |
6 |
|
Saquinavir |
Human |
P |
10.0-10,000 ng/mL |
0.100 |
LC-MS/MS |
6 |
| |
| Dapsone |
Dapsone |
Human |
P |
5.00-2,000 ng/mL |
0.100 |
LC-MS/MS |
2 |
|
Debrisoquine |
Human |
P |
5.00-2,000 ng/mL |
0.100 |
LC-MS/MS |
2 |
|
Mephenytoin |
Human |
P |
5.00-2,000 ng/mL |
0.100 |
LC-MS/MS |
2 |
|
Tolbutamide |
Human |
P |
5.00-2,000 ng/mL |
0.100 |
LC-MS/MS |
2 |
|
Theophylline |
Human |
P |
5.00-2,000 ng/mL |
0.100 |
LC-MS/MS |
2 |
| |
| Debrisoquine |
Debrisoquine |
Human |
P |
5.00-2,000 ng/mL |
0.100 |
LC-MS/MS |
2 |
|
Dapsone |
Human |
P |
5.00-2,000 ng/mL |
0.100 |
LC-MS/MS |
2 |
|
Mephenytoin |
Human |
P |
5.00-2,000 ng/mL |
0.100 |
LC-MS/MS |
2 |
|
Tolbutamide |
Human |
P |
5.00-2,000 ng/mL |
0.100 |
LC-MS/MS |
2 |
|
Theophylline |
Human |
P |
5.00-2,000 ng/mL |
0.100 |
LC-MS/MS |
2 |
| |
| Ethinyl Estradiol |
Ethinyl Estradiol |
Human |
P |
2.50-500 pg/mL |
0.500 |
LC-MS/MS |
2 |
|
Norethindrone |
Human |
P |
50.0-10,000 pg/mL |
0.500 |
LC-MS/MS |
2 |
| |
| IL-1β |
IL-1β |
Human |
S |
15.0-5,000 pg/mL |
0.200 |
ECL |
N |
|
IL-6 |
Human |
S |
15.0-5,000 pg/mL |
0.200 |
ECL |
N |
|
TNF-α |
Human |
S |
15.0-5,000 pg/mL |
0.200 |
ECL |
N |
| |
| IL-6 |
IL-6 |
Human |
S |
15.0-5,000 pg/mL |
0.200 |
ECL |
N |
|
IL-1β |
Human |
S |
15.0-5,000 pg/mL |
0.200 |
ECL |
N |
|
TNF-α |
Human |
S |
15.0-5,000 pg/mL |
0.200 |
ECL |
N |
| |
| Indinavir |
Indinavir |
Human |
P |
10.0-10,000 ng/mL |
0.100 |
LC-MS/MS |
6 |
|
Amprenavir |
Human |
P |
10.0-10,000 ng/mL |
0.100 |
LC-MS/MS |
6 |
|
Nelfinavir |
Human |
P |
10.0-10,000 ng/mL |
0.100 |
LC-MS/MS |
6 |
|
Ritonavir |
Human |
P |
10.0-10,000 ng/mL |
0.100 |
LC-MS/MS |
6 |
|
Saquinavir |
Human |
P |
10.0-10,000 ng/mL |
0.100 |
LC-MS/MS |
6 |
| |
| Lopinavir |
Lopinavir |
Human |
P |
20.0-20,000 ng/mL |
0.100 |
LC-MS/MS |
6 |
|
Ritonavir |
Human |
P |
10.0-10,000 ng/mL |
0.100 |
LC-MS/MS |
6 |
| |
| Lopinavir |
Lopinavir |
Human |
P |
20.0-20,000 ng/mL |
0.050 |
LC-MS/MS |
2 |
|
Ritonavir |
Human |
P |
10.0-2,000 ng/mL |
0.050 |
LC-MS/MS |
2 |
| |
| Mephenytoin |
Mephenytoin |
Human |
P |
5.00-2,000 ng/mL |
0.100 |
LC-MS/MS |
2 |
|
Dapsone |
Human |
P |
5.00-2,000 ng/mL |
0.100 |
LC-MS/MS |
2 |
|
Debrisoquine |
Human |
P |
5.00-2,000 ng/mL |
0.100 |
LC-MS/MS |
2 |
|
Tolbutamide |
Human |
P |
5.00-2,000 ng/mL |
0.100 |
LC-MS/MS |
2 |
|
Theophylline |
Human |
P |
5.00-2,000 ng/mL |
0.100 |
LC-MS/MS |
2 |
| |
| Nelfinavir |
Nelfinavir |
Human |
P |
10.0-10,000 ng/mL |
0.100 |
LC-MS/MS |
6 |
|
Amprenavir |
Human |
P |
10.0-10,000 ng/mL |
0.100 |
LC-MS/MS |
6 |
|
Indinavir |
Human |
P |
10.0-10,000 ng/mL |
0.100 |
LC-MS/MS |
6 |
|
Ritonavir |
Human |
P |
10.0-10,000 ng/mL |
0.100 |
LC-MS/MS |
6 |
|
Saquinavir |
Human |
P |
10.0-10,000 ng/mL |
0.100 |
LC-MS/MS |
6 |
| |
| Norethindrone |
Norethindrone |
Human |
P |
50.0-10,000 pg/mL |
0.500 |
LC-MS/MS |
2 |
|
Ethinyl Estradiol |
Human |
P |
2.50-500 pg/mL |
0.500 |
LC-MS/MS |
2 |
| |
| Ritonavir |
Ritonavir |
Human |
P |
10.0-10,000 ng/mL |
0.100 |
LC-MS/MS |
6 |
|
Indinavir |
Human |
P |
10.0-10,000 ng/mL |
0.100 |
LC-MS/MS |
6 |
|
Nelfinavir |
Human |
P |
10.0-10,000 ng/mL |
0.100 |
LC-MS/MS |
6 |
|
Saquinavir |
Human |
P |
10.0-10,000 ng/mL |
0.100 |
LC-MS/MS |
6 |
|
Amprenavir |
Human |
P |
10.0-10,000 ng/mL |
0.100 |
LC-MS/MS |
6 |
| |
| Ritonavir |
Ritonavir |
Human |
P |
10.0-10,000 ng/mL |
0.100 |
LC-MS/MS |
6 |
|
Amprenavir |
Human |
P |
10.0-10,000 ng/mL |
0.100 |
LC-MS/MS |
6 |
| |
| Ritonavir |
Ritonavir |
Human |
P |
10.0-2,000 ng/mL |
0.050 |
LC-MS/MS |
6 |
|
Lopinavir |
Human |
P |
20.0-20,000 ng/mL |
0.050 |
LC-MS/MS |
6 |
| |
| Ritonavir |
Ritonavir |
Human |
P |
10.0-2,000 ng/mL |
0.050 |
LC-MS/MS |
2 |
|
Lopinavir |
Human |
P |
20.0-20,000 ng/mL |
0.050 |
LC-MS/MS |
2 |
| |
| Saquinavir |
Saquinavir |
Human |
P |
10.0-10,000 ng/mL |
0.100 |
LC-MS/MS |
6 |
|
Amprenavir |
Human |
P |
10.0-10,000 ng/mL |
0.100 |
LC-MS/MS |
6 |
|
Indinavir |
Human |
P |
10.0-10,000 ng/mL |
0.100 |
LC-MS/MS |
6 |
|
Nelfinavir |
Human |
P |
10.0-10,000 ng/mL |
0.100 |
LC-MS/MS |
6 |
|
Ritonavir |
Human |
P |
10.0-10,000 ng/mL |
0.100 |
LC-MS/MS |
6 |
| |
| Tenofovir |
Tenofovir |
Human |
P |
1.00-200 ng/mL |
0.100 |
LC-MS/MS |
2 |
|
Adefovir |
Human |
P |
1.00-200 ng/mL |
0.100 |
LC-MS/MS |
2 |
| |
| Tenofovir |
Tenofovir |
Human |
U |
50.0-5,000 ng/mL |
0.050 |
LC-MS/MS |
N |
|
Adefovir |
Human |
U |
50.0-5,000 ng/mL |
0.050 |
LC-MS/MS |
N |
| |
| Theophylline |
Theophylline |
Human |
P |
5.00-2,000 ng/mL |
0.100 |
LC-MS/MS |
2 |
|
Dapsone |
Human |
P |
5.00-2,000 ng/mL |
0.100 |
LC-MS/MS |
2 |
|
Debrisoquine |
Human |
P |
5.00-2,000 ng/mL |
0.100 |
LC-MS/MS |
2 |
|
Mephenytoin |
Human |
P |
5.00-2,000 ng/mL |
0.100 |
LC-MS/MS |
2 |
|
Tolbutamide |
Human |
P |
5.00-2,000 ng/mL |
0.100 |
LC-MS/MS |
2 |
| |
| Tolbutamide |
Tolbutamide |
Human |
P |
5.00-2,000 ng/mL |
0.100 |
LC-MS/MS |
2 |
|
Theophylline |
Human |
P |
5.00-2,000 ng/mL |
0.100 |
LC-MS/MS |
2 |
|
Dapsone |
Human |
P |
5.00-2,000 ng/mL |
0.100 |
LC-MS/MS |
2 |
|
Debrisoquine |
Human |
P |
5.00-2,000 ng/mL |
0.100 |
LC-MS/MS |
2 |
|
Mephenytoin |
Human |
P |
5.00-2,000 ng/mL |
0.100 |
LC-MS/MS |
2 |
| |
| TNF-α |
TNF-α |
Human |
S |
15.0-5,000 pg/mL |
0.200 |
ECL |
N |
|
IL-1β |
Human |
S |
15.0-5,000 pg/mL |
0.200 |
ECL |
N |
|
IL-6 |
Human |
S |
15.0-5,000 pg/mL |
0.200 |
ECL |
N |
|